SGHT

MKT CAP:$235M

Sight Sciences, Inc.

Market Cap

$235M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$4.20-$3.28 (-43.87%)

Apr 21, 2026

Company Details

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a ...

CEO

Paul Badawi

IPO Date

Jul 15, 2021

Website

www.sightsciences.com

Key Metrics TTM

Revenue

$77M

-3.1% YoY

Net Income

-$38M

EPS (Diluted)

-$0.75

Free Cash Flow

-$30M

Revenue / Share

$1.46

Gross Margin

86.2%

Operating Margin

-48.0%

Net Margin

-49.7%

FCF Margin

-38.7%

P/S

3.0x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 4, 2026

$77M-3.1%EPS -$0.74

Q4 2025

Mar 4, 2026

$20M+6.9%EPS -$0.08

Q3 2025

Nov 6, 2025

$20M-1.2%EPS -$0.16

Q2 2025

Aug 7, 2025

$20M-8.5%EPS -$0.23

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$15M	$12M	-$22M
Q2 22	$17M	$14M	-$23M
Q3 22	$19M	$16M	-$22M
Q4 22	$21M	$17M	-$17M
Q1 23	$19M	$16M	-$18M
Q2 23	$23M	$20M	-$15M
Q3 23	$20M	$17M	-$13M
Q4 23	$19M	$16M	-$11M
Q1 24	$19M	$16M	-$15M
Q2 24	$21M	$18M	-$13M
Q3 24	$20M	$17M	-$11M
Q4 24	$19M	$17M	-$12M
Q1 25	$18M	$15M	-$14M
Q2 25	$20M	$17M	-$12M
Q3 25	$20M	$17M	-$8M
Q4 25	$20M	$18M	-$4M

Valuation

Quarter	P/S	P/E
Q1 22	4.3x	—
Q2 22	3.9x	—
Q3 22	3.6x	—
Q4 22	3.3x	—
Q1 23	3.1x	—
Q2 23	2.9x	—
Q3 23	2.8x	—
Q4 23	2.9x	—
Q1 24	2.9x	—
Q2 24	3.0x	—
Q3 24	3.0x	—
Q4 24	2.9x	—
Q1 25	3.0x	—
Q2 25	3.1x	—
Q3 25	3.1x	—
Q4 25	3.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$22M	-$22M
Q2 22	-$18M	-$19M
Q3 22	-$20M	-$20M
Q4 22	-$16M	-$16M
Q1 23	-$17M	-$18M
Q2 23	-$13M	-$14M
Q3 23	-$10M	-$10M
Q4 23	-$6M	-$7M
Q1 24	-$10M	-$10M
Q2 24	-$10M	-$10M
Q3 24	$600.0K	$549.0K
Q4 24	-$3M	-$4M
Q1 25	-$12M	-$12M
Q2 25	-$8M	-$8M
Q3 25	-$9M	-$9M
Q4 25	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q1 22	$227.0K
Q2 22	$342.0K
Q3 22	$272.0K
Q4 22	$129.0K
Q1 23	$126.0K
Q2 23	$97.0K
Q3 23	$304.0K
Q4 23	$264.0K
Q1 24	$117.0K
Q2 24	$80.0K
Q3 24	$51.0K
Q4 24	$137.0K
Q1 25	$0
Q2 25	$210.0K
Q3 25	$170.0K
Q4 25	$156.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+72.3%	+82.7%
Q2 22	+37.4%	+69.8%
Q3 22	+42.6%	+49.4%
Q4 22	+39.9%	+27.9%
Q1 23	+26.5%	-1.8%
Q2 23	+36.2%	-3.6%
Q3 23	+7.1%	-17.5%
Q4 23	-8.7%	-20.6%
Q1 24	+2.3%	-6.6%
Q2 24	-9.0%	-12.0%
Q3 24	+0.7%	-6.1%
Q4 24	+1.7%	+3.8%
Q1 25	-9.1%	-7.7%
Q2 25	-8.5%	-8.2%
Q3 25	-1.2%	-11.4%
Q4 25	+6.9%	-22.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$3M	20.0%
Q2 22	$4M	20.5%
Q3 22	$3M	17.3%
Q4 22	$3M	15.7%
Q1 23	$4M	18.7%
Q2 23	$4M	15.9%
Q3 23	$4M	19.3%
Q4 23	$3M	18.5%
Q1 24	$5M	23.4%
Q2 24	$0	0.0%
Q3 24	$4M	21.4%
Q4 24	$4M	20.7%
Q1 25	$4M	24.2%
Q2 25	$4M	19.6%
Q3 25	$2M	12.2%
Q4 25	$3M	12.5%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$6M	—	—	$28M
Q2 22	$6M	—	—	$31M
Q3 22	$6M	—	—	$32M
Q4 22	$5M	$26M	$3M	—
Q1 23	$5M	—	—	$29M
Q2 23	$5M	—	—	$30M
Q3 23	$4M	—	—	$27M
Q4 23	$3M	$22M	$2M	—
Q1 24	$5M	—	—	$27M
Q2 24	$4M	—	—	$27M
Q3 24	$5M	—	—	$23M
Q4 24	$4M	$23M	$1M	—
Q1 25	$4M	—	—	$25M
Q2 25	$4M	—	—	$24M
Q3 25	$3M	—	—	$22M
Q4 25	$2M	—	—	$19M

Revenue Segments

Quarter	Dry Eye	Surgical Glaucoma
Q1 22	$1M	$14M
Q2 22	$1M	$16M
Q3 22	$2M	$17M
Q4 22	$2M	$19M
Q1 23	$1M	$17M
Q2 23	$1M	$21M
Q3 23	$2M	$18M
Q1 24	$1M	$18M
Q2 24	$1M	$20M
Q3 24	$2M	$19M
Q4 24	$305.0K	$19M
Q1 25	$394.0K	$17M
Q2 25	$333.0K	$19M
Q3 25	$188.0K	$20M
Q4 25	$724.0K	$20M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$239M	$0	$239M
Q2 22	$220M	$0	$220M
Q3 22	$200M	$0	$200M
Q4 22	$185M	$0	$185M
Q1 23	$167M	$0	$167M
Q2 23	$155M	$0	$155M
Q3 23	$145M	$0	$145M
Q4 23	$138M	$0	$138M
Q1 24	$127M	$0	$127M
Q2 24	$118M	$0	$118M
Q3 24	$119M	$0	$119M
Q4 24	$120M	$0	$120M
Q1 25	$109M	$0	$109M
Q2 25	$102M	$0	$102M
Q3 25	$92M	$0	$92M
Q4 25	$92M	$0	$92M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	48M	+0.4%	+12.6%
Q2 22	48M	+0.3%	+12.9%
Q3 22	48M	+0.4%	+20.2%
Q4 22	48M	+0.6%	+1.7%
Q1 23	48M	+0.4%	+1.8%
Q2 23	49M	+0.3%	+1.8%
Q3 23	49M	+0.3%	+1.6%
Q4 23	49M	+0.5%	+1.4%
Q1 24	49M	+1.2%	+2.2%
Q2 24	50M	+0.8%	+2.8%
Q3 24	50M	+0.9%	+3.4%
Q4 24	51M	+0.9%	+3.9%
Q1 25	51M	+1.0%	+3.6%
Q2 25	52M	+1.0%	+3.8%
Q3 25	52M	+1.1%	+4.0%
Q4 25	53M	+1.3%	+4.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$70.2K	212
Q2 22	$81.3K	212
Q3 22	$88.1K	212
Q4 22	$82.2K	250
Q1 23	$75.3K	250
Q2 23	$93.9K	250
Q3 23	$80.0K	250
Q4 23	$87.6K	214
Q1 24	$90.0K	214
Q2 24	$99.9K	214
Q3 24	$94.2K	214
Q4 24	$88.3K	216
Q1 25	$81.1K	216
Q2 25	$90.6K	216
Q3 25	$92.2K	216
Q4 25	$109.6K	186

Revenue / Employee